Physician profile
Stephen L Thomas
NPI 1508849985
$1,424.03
in general payments reported to CMS, 2019-2025
25 companies · $180 in 2025
The $180 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $195 · 2020: $200 · 2021: $345 · 2022: $173 · 2023: $188 · 2024: $143 · 2025: $180.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $511.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $511.19 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $189.07 | 2021-2023 | Ubrelvy, Viberzi, Linzess |
| Abbott Laboratories | $161.16 | 2019-2023 | Freestyle Libre 3, Proclaim |
| Allergan, INC. | $107.60 | 2019-2020 | |
| Astellas Pharma US INC | $102.63 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $100.13 | 2020-2024 | Trelegy Ellipta, Shingrix |
| Novo Nordisk INC | $94.84 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Boston Scientific Corporation | $87.02 | 2019-2025 | Watchman Flx |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $72.27 | 2019-2022 | |
| Pfizer INC. | $68.65 | 2019-2025 | |
| Dexcom, INC. | $66.69 | 2024-2025 | Dexcom G6 Transmitter |
| Lucid Diagnostics INC. | $59.48 | 2021 | |
| Janssen Pharmaceuticals, INC | $55.04 | 2020-2023 | Spravato |
| Novartis Pharmaceuticals Corporation | $47.64 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.88 | 2019-2020 | |
| Ferring Pharmaceuticals INC. | $19.45 | 2025 | Euflexxa |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.17 | 2020 | |
| Teleflex LLC | $17.30 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $16.75 | 2022 | |
| Inspire Medical Systems, INC. | $16.03 | 2025 | Inspire |
| Idorsia Pharmaceuticals US INC | $15.85 | 2022 | |
| Saluda Medical Americas, INC. | $15.35 | 2024 | Evoke |
| Mylan Specialty L.P. | $15.19 | 2023 | Yupelri |
| Vertos Medical, INC. | $15.06 | 2023 | Mild Device Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $14.03 | 2022 | |
| Amarin Pharma, INC. | $11.75 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.